Identification of a novel estrogen response element in the Breast Cancer Resistance Protein (ABCG2) gene

• Published in: Cancer research (Chicago, Ill.) Ill.), 2004-02, Vol.64 (4), p.1247-1251
• Main Authors: EE, Pui Lai, KAMALAKARAN, Sitharthan, TONETTI, Debra, XIAOLONG HE, ROSS, Douglas D, BECK, William T
• Format: Article
• Language: English
• Subjects: Antineoplastic agents; ATP Binding Cassette Transporter, Sub-Family G, Member 2; ATP-Binding Cassette Transporters - genetics; Biological and medical sciences; Estrogen Receptor alpha; Estrogens - pharmacology; Female; Humans; Medical sciences; Mutagenesis, Site-Directed; Neoplasm Proteins - genetics; Pharmacology. Drug treatments; Promoter Regions, Genetic; Receptors, Estrogen - metabolism; Response Elements; RNA, Messenger - analysis; Tumors
• ISSN: 0008-5472; 1538-7445
• DOI: 10.1158/0008-5472.can-03-3583

The breast cancer resistance protein (BCRP) is an ATP-binding cassette half transporter that confers resistance to anticancer drugs such as mitoxantrone, anthracyclines, topotecan, and SN-38. Initial characterization of the BCRP promoter revealed that it is TATA-less with 5 putative Sp1 sites downstream from a putative CpG island and several AP1 sites (K. J. Bailey-Dell et al., Biochim. Biophys. Acta, 1520: 234-241, 2001). Here, we examined the sequence of the 5'-flanking region of the BCRP gene and found a putative estrogen response element (ERE). We showed that estrogen enhanced the expression of BCRP mRNA in the estrogen receptor (ER)-positive T47D:A18 cells and PA-1 cells stably expressing ERalpha. In BCRP promoter-luciferase assays, sequential deletions of the BCRP promoter showed that the region between -243 and -115 is essential for the ER effect. Mutation of the ERE found within this region attenuated the estrogen response, whereas deletion of the site completely abrogated the estrogen effect. Furthermore, electrophoretic mobility shift assays revealed specific binding of ERalpha to the BCRP promoter through the identified ERE. Taken together, we provide evidence herein for a novel ERE in the BCRP promoter.